BD Predicts Doubling Of Infusion Therapy In Wake Of Ohmeda Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Becton Dickinson expects to more than double its infusion therapy (IT) business to $500 mil. in 1999, the first full fiscal year following the company's acquisition of Ohmeda's medical device division, IT worldwide division president Bob Adrion told analysts April 28 in New York City. For 1997, BD reported IT product sales of $228 mil.